ArticleBiomarker research2023
Radiogenomic association of deep MR imaging features with genomic profiles and clinical characteristics in breast cancer.
Article in Biomarker research, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed.
- Artificial intelligence construction: a review of the bridge between CT imaging features of lung ground-glass nodules adenocarcinoma and carcinogenic driver genes.Journal of cancer research and clinical oncology · 2026Review
- AI-powered radiogenomics: imaging-driven diagnosis and discovery of cancer's molecular and cellular landscape.Molecular genetics and genomics : MGG · 2026Review
- Review
- Artificial intelligence-driven multimodal fusion for precision diagnosis and personalized management of breast cancer.Oncology reviews · 2026Review
- Radiomics and Deep Learning: Bridging Breast Cancer Imaging Phenotypes and Genomic Heterogeneity.Breast cancer (Dove Medical Press) · 2026Review
- Review
- Beyond Imaging: Integrating Radiomics, Genomics, and Multi-Omics for Precision Breast Cancer Management.Cancers · 2025Review
- Multimodal imaging and advanced quantitative techniques for HER-2 status prediction in breast cancer.Discover oncology · 2025Review
- Q RadFusion: Hybrid Quantum Classical Radiogenomic Framework for Breast Cancer Diagnosis.Research square · 2025Article
- A Dynamic Contrast-Enhanced MRI-Based Vision Transformer Model for Distinguishing HER2-Zero, -Low, and -Positive Expression in Breast Cancer and Exploring Model Interpretability.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2025Article
- Spatial-temporal radiogenomics in predicting neoadjuvant chemotherapy efficacy for breast cancer: a comprehensive review.Journal of translational medicine · 2025Review
- Article
- The impact of radiogenomics on breast cancer.American journal of cancer research · 2025Review
- Radiomics in breast cancer: Current advances and future directions.Cell reports. Medicine · 2024Review
- Identification of clear cell renal cell carcinoma subtypes by integrating radiomics and transcriptomics.Heliyon · 2024Article
- Lymph node metastasis prediction and biological pathway associations underlying DCE-MRI deep learning radiomics in invasive breast cancer.BMC medical imaging · 2024Article
- Clinico-genomic findings, molecular docking, and mutational spectrum in an understudied population with breast cancer patients from KP, Pakistan.Frontiers in genetics · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundIt has been believed that traditional handcrafted radiomic features extracted from magnetic resonance imaging (MRI) of tumors are normally shallow and low-ordered. Recent advancement in deep learning technology shows that the high-order deep radiomic features extracted automatically from tumor images can capture tumor heterogeneity in a more efficient way. We hypothesize that MRI-based deep radiomic phenotypes have significant associations with molecular profiles of breast cancer tumors. We aim to identify deep radiomic features (DRFs) from MRI, evaluate their significance in predicting breast cancer (BC) clinical characteristics and explore their associations with multi-level genomic factors.
methodsA denoising autoencoder was built to retrospectively extract 4,096 DRFs from 110 BC patients' MRI. Visualization and clustering were applied to these DRFs. Linear Mixed Effect models were used to test their associations with multi-level genomic features (GFs) (risk genes, gene signatures, and biological pathway activities) extracted from the same patients' mRNA expression profile. A Least Absolute Shrinkage and Selection Operator model was used to identify the most predictive DRFs for each clinical characteristic (tumor size (T), lymph node metastasis (N), estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor 2 (HER2) status).
resultsThirty-six conventional radiomic features (CRFs) for 87 of the 110 BC patients provided by a previous study were used for comparison. More than 1,000 DRFs were associated with the risk genes, gene signatures, and biological pathways activities (adjusted P-value < 0.05). DRFs produced better performance in predicting T, N, ER, PR, and HER2 status (AUC > 0.9) using DRFs. These DRFs showed significant powers of stratifying patients, linking to relevant biological and clinical characteristics. As a contrast, only eight risk genes were associated with CRFs. The RFs performed worse in predicting clinical characteristics than DRFs.
conclusionsThe deep learning-based auto MRI features perform better in predicting BC clinical characteristics, which are more significantly associated with GFs than traditional semi-auto MRI features. Our radiogenomic approach for identifying MRI-based imaging signatures may pave potential pathways for the discovery of genetic mechanisms regulating specific tumor phenotypes and may enable a more rapid innovation of novel imaging modalities, hence accelerating their translation to personalized medicine.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.